<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: A case of probable <z:chebi fb="0" ids="3441">carvedilol</z:chebi>-induced <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> is reported </plain></SENT>
<SENT sid="1" pm="."><plain>SUMMARY: A 64-year-old African-American woman with a history of <z:hpo ids='HP_0000822'>hypertension</z:hpo>, diastolic dysfunction, mild <z:hpo ids='HP_0001712'>left-ventricular hypertrophy</z:hpo>, and <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> was hospitalized with a platelet count of 94,000 platelets/mm(3) </plain></SENT>
<SENT sid="2" pm="."><plain>Dalteparin, <z:chebi fb="8" ids="10033">warfarin</z:chebi>, and <z:chebi fb="0" ids="3441">carvedilol</z:chebi> had recently been added to her medication regimen </plain></SENT>
<SENT sid="3" pm="."><plain>Beta-2-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> immunoglobulin G (IgG) antibody, anticardiolipin IgG, and anticardiolipin immunoglobulin M tests, conducted to rule out <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, revealed values within the <z:mpath ids='MPATH_458'>normal</z:mpath> range </plain></SENT>
<SENT sid="4" pm="."><plain>After the exclusion of dalteparin, hydrochlorothiazide, and other causes of drug- and non-drug-related <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:chebi fb="0" ids="3441">carvedilol</z:chebi> was discontinued and replaced with <z:chebi fb="0" ids="6904">metoprolol</z:chebi> <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>After this substitution, the patient's platelet count continued to rise </plain></SENT>
<SENT sid="6" pm="."><plain>On hospital day 10, the patient was discharged to home on low-molecular-weight <z:chebi fb="5" ids="28304">heparin</z:chebi> bridging therapy, <z:chebi fb="0" ids="10034">warfarin sodium</z:chebi> 5 mg orally daily, <z:chebi fb="10" ids="8776">ranitidine</z:chebi> 150 mg orally daily, <z:chebi fb="0" ids="6904">metoprolol</z:chebi> <z:chebi fb="1" ids="15193,50562">tartrate</z:chebi> 75 mg orally twice daily, <z:chebi fb="0" ids="43755">lisinopril</z:chebi> 20 mg orally daily, <z:chebi fb="0" ids="2668">amlodipine</z:chebi> 10 mg orally daily, <z:chebi fb="0" ids="17439">cyanocobalamin</z:chebi> 1000 mg orally daily, and two tablets of hydrochlorothiazide 25 mg-triamterene 37.5 mg orally daily </plain></SENT>
<SENT sid="7" pm="."><plain>Her platelet count was 319,000 platelets/mm(3) on the day of discharge and remained stable thereafter </plain></SENT>
<SENT sid="8" pm="."><plain>The recovery time of the platelets coincided with the elimination half-life of <z:chebi fb="0" ids="3441">carvedilol</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: A woman developed <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, first noticed as a reduction in the platelet count to a low-<z:mpath ids='MPATH_458'>normal</z:mpath> value, 17 days after treatment with <z:chebi fb="0" ids="3441">carvedilol</z:chebi> was begun </plain></SENT>
<SENT sid="10" pm="."><plain>Other possible culprit drugs were withdrawn, but the platelet count continued to drop until <z:chebi fb="0" ids="3441">carvedilol</z:chebi> was discontinued </plain></SENT>
<SENT sid="11" pm="."><plain>The platelet count rose on the day of <z:chebi fb="0" ids="3441">carvedilol</z:chebi> removal and was within the <z:mpath ids='MPATH_458'>normal</z:mpath> range within another day </plain></SENT>
</text></document>